Etxeberria, Iñaki http://orcid.org/0000-0003-2713-0836
Glez-Vaz, Javier http://orcid.org/0000-0001-8936-190X
Teijeira, Álvaro
Melero, Ignacio
Clinical trials referenced in this document:
Documents that mention this clinical trial
New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
https://doi.org/10.1136/esmoopen-2020-000733
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2023-007364
Documents that mention this clinical trial
New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
https://doi.org/10.1136/esmoopen-2020-000733
Documents that mention this clinical trial
New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
https://doi.org/10.1136/esmoopen-2020-000733
Documents that mention this clinical trial
New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
https://doi.org/10.1136/esmoopen-2020-000733
Documents that mention this clinical trial
12 Key pharmacokinetic and pharmacodynamic parameters that correlate with the anti-tumor activity of a bispecific PD-L1 conditional 4–1BB agonist
https://doi.org/10.1136/jitc-2021-sitc2021.012
New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
https://doi.org/10.1136/esmoopen-2020-000733
742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors
https://doi.org/10.1136/jitc-2023-sitc2023.0742
Documents that mention this clinical trial
New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
https://doi.org/10.1136/esmoopen-2020-000733
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
https://doi.org/10.1136/jitc-2021-003532
This article is maintained by: Elsevier
Article Title: New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
Journal Title: ESMO Open
CrossRef DOI link to publisher maintained version: https://doi.org/10.1136/esmoopen-2020-000733
Content Type: article
Copyright: © 2020 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.